| Name | Title | Contact Details |
|---|---|---|
Jessica Young |
Director, US Marketing | Profile |
Brian Roberts |
Senior Corporate Counsel, Head of Contracts and Research and Development Counsel | Profile |
Amy Finnigan |
Sr. Director, IT R&D | Profile |
Mardi Dier |
Chief Financial Officer | Profile |
Nathan Rapp |
Associate Director, Employee Relations | Profile |
The Clemson University Biomedical Engineering Innovation Campus develops high-impact medical technology and devices for disease management and technology transfer from bench to bedside.
We are dedicated to discovering novel biological targets and developing drugs that profoundly improve the lives of people born with rare metabolic defects who are unable to sustain basic biochemical processes necessary for life.
miRagen Therapeutics, Inc., is a biopharmaceutical company discovering and developing innovative microRNA (miRNA)-targeting therapies to improve human health, specifically in disease areas of high unmet medical need. The company leverages in-house expertise in miRNA biology, oligonucleotide chemistry, and drug development to evaluate and advance best-in-class technologies and high-potential drug candidates for its own pipeline or in conjunction with strategic partners. From its founding, miRagen has developed ongoing, collaborative relationships with academic institutions that give the company unique access to the most promising early-stage discoveries. This access to groundbreaking science provides a significant strategic advantage in the rapidly-developing field of miRNA-targeting therapeutics.
Response Genetics is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Telik is a Palo Alto, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.